tool compound

EPZ020411 is a specific and effective inhibitor of PRMT6 (IC50=10 nM).

Atinvicitinib, a selective Janus kinase (JAK) inhibitor, demonstrates high specificity for Janus kinase 1 (JAK1), consequently inhibiting downstream cytokine signaling pathways that rely on JAK1 enzymatic activity. Atinvicitinib modulates a wide range of cytokines that are implicated in itch responses, allergic reactions, and inflammatory conditions, making it a significant research tool for studying cytokine-mediated immune processes as well as therapeutic modulation of allergic and inflammatory diseases.

3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in the study of neurological disorders and cancer.

Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable, small-molecule, reversible, and direct antagonist of Factor XIa (FXIa). It exhibits potent inhibitory activity across species, with Ki values of 0.11 nM for human, 0.38 nM for rabbit, and 0.64 nM for dog. By targeting FXIa, Milvexian selectively inhibits the intrinsic pathway of the coagulation cascade. It demonstrates robust antithrombotic efficacy in various in vitro and in vivo models while maintaining a favorable safety profile regarding bleeding risk. It is a critical tool for investigating novel anticoagulant strategies in thrombosis and cardiovascular research.

BRK inhibitor P21d hydrochloride is a highly potent inhibitor of breast tumor kinase (BRK/PTK6), displaying an IC50 of 30 nM, and effectively suppresses p-SAM68 with an IC50 of 52 nM. This compound serves as a valuable tool for evaluating BRK inhibitors' efficacy in xenograft breast tumor models, enabling in vivo activity assessment.

CC214-1 is an mTOR inhibitor with potential anticancer activity, inhibits protein translation, and induces autophagy. CC214-1 is an in vitro tool compound for exploring the biology of mTOR kinases and can be used to study myeloma.

JAK3-IN-11 (Compound 12) exhibits potent, noncytotoxic, irreversible, orally active JAK3 inhibitory activity (IC50 = 1.7 nM) with an excellent selectivity profile (>588-fold compared to other JAK isoforms), covalently binds to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T-cell proliferation which is a promising tool for studying autoimmune diseases [1].

2-Acetoxyacetophenone is an organic ester compound that is commonly employed as a reagent and biochemical tool in the field of proteomics research, with additional potential applications in specialized chemical synthesis and various branches of medical research.

5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione) is a synthetic compound. It has been used as a catalyst and as a tool in enzyme kinetic studies; it has also been used in studies of enzyme inhibition, as well as in drug receptor interaction studies.

Compound 84163-77-9 is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 84163-77-9 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

CA-II/TNAP-IN-1 is a novel 1,3-disubstituted thiourea derivative that acts as a dual inhibitor of carbonic anhydrase II (CA-II) and tissue-nonspecific alkaline phosphatase (TNAP). The compound is an essential tool for investigating cancer metabolism and enzyme-mediated tumor microenvironment regulation, aiming to enhance anti-tumor efficacy by jointly inhibiting key enzymes involved in pH regulation and mineralization.

GABAA receptor agent 5 demonstrates antagonist activity across multiple GABAA receptor subtypes, and GABAA receptor agent 5 exhibits IC50 values of 0.24, 0.088, 0.068, 0.33, 0.79, 0.32, 0.079, and 0.051 μM for α1β2δ, α4β1δ, α4β2δ, α6β2δ, α1β2γ2, α2β2γ2, α3β2γ2, and α5β2γ2 receptor configurations, respectively. GABAA receptor agent 5 (compound 018) thereby provides a precise pharmacological tool for characterizing subtype-selective GABAA receptor inhibition and supports mechanistic neuropharmacology studies focused on inhibitory synaptic signaling and therapeutic antagonist development.

Tebideutorexant is a selective antagonist of the orexin-1 receptor and has demonstrated anti-panic effects in both rodent and human models of panic-anxiety. Tebideutorexant provides valuable insights into orexin signaling pathways in stress response and has potential utility as a tool compound for psychiatric and neurobehavioral disorder research.

FLA-99 is a biochemical compound that selectively inhibits the enzymatic breakdown of inositol-1,4,5-triphosphate (IP3) by inositol-1,4,5-triphosphate 5-phosphatase. By preventing IP3 degradation, FLA-99 modulates intracellular calcium signaling, making it a useful tool in signal transduction and phosphoinositide pathway research.

Compound TYD-02596, with CAS No. 333425-29-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound TYD-02596 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Pyrrothiogatain, with CAS No. 477888-48-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr13356 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound 837392-64-0 is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 837392-64-0 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound 69627-03-8 is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 69627-03-8 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound CC50616, with CAS No. 884507-31-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound CC50616 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0007, with CAS No. 676491-46-6, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0007 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0008, with CAS No. 40432-52-8, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0008 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0012, with CAS No. 1384745-48-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0012 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0016, with CAS No. 1363382-07-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0016 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0017, with CAS No. 1352012-69-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0017 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.